Scarica l'app Stockscreener
0.7321
2.39%
-0.0179
Dopo l'orario di chiusura:
.68
-0.0521
-7.12%
Precedente Chiudi:
$0.75
Aprire:
$0.7401
Volume 24 ore:
576.73K
Relative Volume:
0.89
Capitalizzazione di mercato:
$13.54M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+5.76%
1M Prestazione:
+12.63%
6M Prestazione:
-66.57%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$0.7201
$0.75
Intervallo di 1 settimana:
$0.6922
$0.7998
Portata 52W:
$0.6326
$2.75
Metavia Inc Stock (MTVA) Company Profile
Nome
Metavia Inc
Settore
Industria
Telefono
(857) 702-9600
Indirizzo
545 CONCORD AVENUE, CAMBRIDGE
Confronta MTVA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MTVA
Metavia Inc
|
0.7321 | 13.54M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Metavia Inc Stock (MTVA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
Metavia Inc Borsa (MTVA) Ultime notizie
MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th - GlobeNewswire
MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions - Eastern Progress
MetaVia Sees Obesity Opportunities Despite Challenging US Market - insights.citeline.com
MTVA stock touches 52-week low at $0.64 amid market challenges By Investing.com - Investing.com South Africa
MetaVia Inc. receives Nasdaq non-compliance notice - Investing.com Australia
MetaVia Faces Nasdaq Delisting Notice for Low Stock Price - TipRanks
MTVA stock touches 52-week low at $0.64 amid market challenges - Investing.com Nigeria
MetaVia Reports Progress in Obesity and MASH Treatments - TipRanks
MTVA: Additional Positive Topline Results for DA-1726 in Phase 1 MAD Study… - Zacks Small Cap Research
MetaVia Updates Corporate Presentation on DA-1726 Progress - TipRanks
Major Investment Alert: DONG-A ST CO., LTD Boosts Stake in MetaVia! - TipRanks
MetaVia (NASDAQ:MTVA) Price Target Lowered to $3.00 at Maxim Group - Defense World
Maxim Group Lowers MetaVia (MTVA) Price Target to $3.00 | MTVA S - GuruFocus
MetaVia price target lowered to $3 from $6 at Maxim - TipRanks
MetaVia (MTVA) Price Target Cut as Analyst Highlights Future Pro - GuruFocus
MetaVia Inc reports results for the quarter ended March 31Earnings Summary - TradingView
MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update - WV News
MetaVia Completes $10 Million Private Placement - TipRanks
MetaVia launches $10M private placement - MSN
MetaVia secures $10 million in private placement - Investing.com
MetaVia (MTVA) to Raise $10M Through Private Placement | MTVA St - GuruFocus
MetaVia secures $10 million in private placement By Investing.com - Investing.com South Africa
MetaVia announces $10M private placement - TipRanks
MetaVia Inc. announced that it expects to receive $9.995395 million in funding - marketscreener.com
Metavia Announces $10 Million Private Placement Priced At-The-Market Under Nasdaq Rules - marketscreener.com
MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules - Eastern Progress
MetaVia Unveils Promising DA-1241 Trial Results - TipRanks
Asian shares get a lift from plans for China-US trade talks, Beijing stimulus moves - WFMZ.com
MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025 - PR Newswire
Metavia Presents Data On DA-1241, A GPR119 Agonist, Demonstrating Both Hepatoprotective And Glucose-Regulating Effects In Patients With Presumed MASH, At The EASL Congress 2025 - MENAFN.com
Senate confirms Bisignano to lead Social Security Administration as agency faces DOGE overhaul - WFMZ.com
Trump’s meme coin business racks up fees as buyers jump at the chance for access to the president - WFMZ.com
MetaVia Inc expected to post a loss of 60 cents a shareEarnings Preview - TradingView
MetaVia’s Promising Clinical Trial Results and Future Prospects Drive Buy Rating - TipRanks
MetaVia’s DA-1241 shows promise in Phase 2a MASH trial By Investing.com - Investing.com South Africa
Copper Miner Rallies as Takeover Buzz Sparks Investor Optimism - The Globe and Mail
MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025 - Eastern Progress
MetaVia’s DA-1241 shows promise in Phase 2a MASH trial - Investing.com
MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors - insights.citeline.com
MetaVia reports promising obesity drug trial results By Investing.com - Investing.com South Africa
How will MetaVia Inc’s (MTVA) earnings compare to estimates this quarter? - uspostnews.com
RIVN’s Q2 earnings predictions: What the experts say - uspostnews.com
Can Newell Brands Inc (NWL) meet market expectations this quarter? - uspostnews.com
MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential - The Malaysian Reserve
MetaVia (MTVA) Advances DA-1726 in Obesity Treatment with Promis - GuruFocus
MetaVia Reports Positive Phase 1 Trial Results - TipRanks
Metavia Inc Azioni (MTVA) Dati Finanziari
Non sono disponibili dati finanziari per Metavia Inc (MTVA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.91%
1.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):